A Critical Driver of Tumorigenesis and Novel Target for Cancer Therapy
The KDM4 family of histone demethylases (KDM4A, B, C, and D) are epigenetic regulators that have been implicated as drivers of tumorigeneic pathways, including gene overexpression, genomic instability, uncontrolled cell proliferation, inhibition of apoptosis, and metastasis. In addition, KDM4 plays an important role in the self-renewal and maintenance of cancer stem cells.
KDM4 overexpression has been associated with many cancer types, including breast, colorectal, esophageal, prostate, and lymphomas. Thus, KDM4 has emerged as an important novel therapeutic target. Tachyon’s TACH101 is the only KDM4 inhibitor in development.
TACH101 (formerly QC8222) is a potent, selective, first-in-class small molecule inhibitor of all KDM4 proteins. Tachyon is currently developing it for the treatment of advanced or metastatic cancers.
Perabo F, Chandhasin C, Yoo S, Dang V, Del Rosario JR, Chen YK, Stafford JA, Quake SR, Clarke MF. TACH101, a first-in-class pan-inhibitor of KDM4 for treatment of gastrointestinal cancers. J Clin Oncol. 2022. Vol 40, Issue 4 suppl 132 (Feb 1, 2022) 132-132.
Perabo F, Yoo S, Chandhasin C, Del Rosario JR, Chen YK, Filvaroff E, Stafford JA, Quake SR, Clarke MF. Identification of pharmacodynamic and sensitivity biomarkers for TACH101, a pan-inhibitor of KDM4 histone lysine demethylase. Mol Cancer Ther. 2021. Vol 20, suppl 12 (Dec 1, 2021) P086.
Perabo F, Yoo S, Chandhasin C, Del Rosario JR, Chen YK, Filvaroff E, Stafford JA, Quake SR, Clarke MF. TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer. Ann Oncol. 2021. Vol 32, suppl 5 (Sep 1, 2021) S450-S451.
Chandhasin C, Yoo S, Del Rosario J, Chen YK, Stafford JA, Quake SR, Perabo F, Clarke MF. Inhibition of Histone Lysine Demethylases with TACH101, a First-in-Class Pan-Inhibitor of KDM4. J Clin Oncol. 2021. Vol 39, no. 15_suppl (May 20, 2021) 3105-3105.
Yoo S, Chandhasin C, Del Rosario J, Chen YK, Stafford JA, Quake SR, Perabo F, Clarke MF. Pharmacologic characterization of TACH101, a first-in-class KDM4 inhibitor for development as a cancer therapeutic. J Clin Oncol. 2021. Vol 39, no. 15_suppl (May 20, 2021) e15067.
Yoo S, Chandhasin C, Del Rosario J, Chen YK, Stafford JA, Quake SR, Perabo F, Clarke MF. TACH101, a first-in-class pan inhibitor of KDM4 histone lysine demethylases. Cancer Res. 2021. Volume 81, Issue 13 Supplement, pp. 2128.
Metzger E, Stepputtis SS, Strietz J, Preca BT, Urban S, Willmann D, Allen A, Zenk F, Iovino N, Bronsert P, Proske A, Follo M, Boerries M, Stickeler E, Xu J, Wallace MB, Stafford JA, Kanouni T, Maurer J, Schüle R. KDM4 Inhibition Targets Breast Cancer Stem-like Cells. Cancer Res. 2017 Nov 1;77(21):5900-5912.
Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O’Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB. Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett. 2017 Jul 27;8(8):869-874.
Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothenberg ME, Mburu FM, Mantalas GL, Sim S, Clarke MF, Quake SR. Quantitative assessment of single-cell RNA-sequencing methods. Comparative Study Nat Methods. 2014 Jan;11(1):41-6.